Time-kill curves for a semisynthetic glycopeptide, LY333328, against vancomycin-susceptible and vancomycin-resistant Enterococcus faecium strains.
作者信息
Zelenitsky S A, Karlowsky J A, Zhanel G G, Hoban D J, Nicas T
出版信息
Antimicrob Agents Chemother. 1997 Jun;41(6):1407-8. doi: 10.1128/AAC.41.6.1407.
Abstract
摘要
相似文献
1
Time-kill curves for a semisynthetic glycopeptide, LY333328, against vancomycin-susceptible and vancomycin-resistant Enterococcus faecium strains.
Antimicrob Agents Chemother. 1997 Jun;41(6):1407-8. doi: 10.1128/AAC.41.6.1407.
2
Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium.
J Antimicrob Chemother. 2002 Jul;50(1):19-24. doi: 10.1093/jac/dkf058.
3
The in-vitro activity of LY333328, a new glycopeptide, against clinical isolates of vancomycin-resistant enterococci.
Adv Exp Med Biol. 1997;418:483-5. doi: 10.1007/978-1-4899-1825-3_115.
4
Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms.
J Antimicrob Chemother. 1997 Sep;40(3):423-5. doi: 10.1093/jac/40.3.423.
5
In vitro activity of LY333328, a new glycopeptide, against extracellular and intracellular vancomycin-resistant enterococci.
Infection. 2000 Jul-Aug;28(4):214-8. doi: 10.1007/s150100070038.
6
In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.
Antimicrob Agents Chemother. 1997 Oct;41(10):2165-72. doi: 10.1128/AAC.41.10.2165.
7
Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium.
Antimicrob Agents Chemother. 1998 Oct;42(10):2564-8. doi: 10.1128/AAC.42.10.2564.
8
Synergy of an investigational glycopeptide, LY333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple-dose, in vitro pharmacodynamic model.
Antimicrob Agents Chemother. 1999 Mar;43(3):592-7. doi: 10.1128/AAC.43.3.592.
9
In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae.
Diagn Microbiol Infect Dis. 1998 Feb;30(2):89-92. doi: 10.1016/s0732-8893(97)00207-1.
10
Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.
J Antimicrob Chemother. 1998 Feb;41(2):273-6. doi: 10.1093/jac/41.2.273.
引用本文的文献
1
Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection.
Antimicrob Agents Chemother. 2003 May;47(5):1700-6. doi: 10.1128/AAC.47.5.1700-1706.2003.
2
Synergy of an investigational glycopeptide, LY333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple-dose, in vitro pharmacodynamic model.
Antimicrob Agents Chemother. 1999 Mar;43(3):592-7. doi: 10.1128/AAC.43.3.592.
3
Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis.
Antimicrob Agents Chemother. 1999 Jan;43(1):115-20. doi: 10.1128/AAC.43.1.115.
4
In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates.
Antimicrob Agents Chemother. 1998 Sep;42(9):2452-5. doi: 10.1128/AAC.42.9.2452.
5
Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis.
Antimicrob Agents Chemother. 1998 Apr;42(4):981-3. doi: 10.1128/AAC.42.4.981.
Zotero 插件